# Clinical and Commercial Packaging:
## *Delivering the Next Generation of Pharmaceutical Therapies*

**The global pharmaceutical packaging sector is entering a decisive phase of transformation. As pipelines fill with targeted therapies, biologics, and complex drug-device combinations, the role of packaging is expanding well beyond protection and compliance. It now encompasses agility, patient usability, sustainability, and digital traceability – all under mounting regulatory and cost pressures.**

According to Grand View Research, the global pharmaceutical packaging market was valued at USD 139 billion in 2023 and is projected to reach USD 265 billion by 2030 – a CAGR of 9.7%. The contract packaging segment alone is expected to double within a decade, reflecting pharma's growing reliance on outsourcing partners for specialised expertise.

This expansion is matched by complexity. Accelerated development timelines, smaller patient populations, and diverse global markets are reshaping packaging operations from a linear process into a strategic discipline. Whether for oral solid dose (OSD) forms or injectables and drug-device combinations, the common denominator is the need for integrated, flexible, and compliant packaging solutions that can adapt quickly to scientific and commercial realities.

**Agility and Late-Stage Customisation in Oral Solid Dose Packaging**

Traditional packaging strategies were built around scale: long production runs, stable SKUs, and predictable demand. That model is increasingly unfit for purpose in a world of precision medicines and regionalised launches. A more adaptive framework – often referred to as Late-Stage Customisation (LSC) – is now emerging as an industry best practice.

LSC allows manufacturers and CDMOs to postpone the final printing, labelling, or configuration of packaging until demand is clearer or regional destinations are confirmed. Digital printing technologies make this possible: rather than producing large volumes of pre-printed components, companies can maintain a neutral "brite stock" and add variable data, artwork, and language versions at the final stage. It is important to establish the highest common denominator of the core component – whether that is a nude blister, an assembled device, or another base configuration – so manufacturers can still capitalise on larger-volume runs for that shared element while applying appropriately scaled, flexible techniques for market-specific or even named-patient customisation.

This approach tackles what engineers sometimes call the "trumpet syndrome" – where complexity widens downstream as multiple SKUs, languages, and regulatory variants accumulate. Late-stage flexibility narrows that funnel.

The benefits extend across the product lifecycle:

- **Reduced waste and inventory –** fewer obsolete printed components and more efficient warehouse utilisation.
- **Accelerated speed-to-market –** particularly for drugs with short shelf lives or limited stability data.
- **Enhanced compliance –** real-time adaptation to regulatory or language changes.
- **Improved working capital –** less money tied up in pre-configured packaging stock.

LSC can be implemented at several levels, from simple on-demand printing purchased from suppliers to fully integrated in-house systems that print everything from lidding foil to patient inserts. The choice depends on a company's investment appetite and throughput needs.

For clinical programmes – where protocols evolve and batch sizes remain small – on-demand labelling offers critical agility. For commercial production, integrated digital printing and serialisation capabilities ensure consistency and traceability across markets. Increasingly, automation, AI-driven forecasting, and even blockchain-based traceability are being layered on top to enhance responsiveness and oversight.

In short, agility is replacing volume as the defining measure of efficiency. For OSD products, late-stage customisation has become one of the most effective levers to achieve that flexibility without compromising quality or compliance.

**High-Potent Packaging: Safety, Containment, and Control**

The industry's pivot toward highly potent active pharmaceutical ingredients (HPAPIs) – particularly in oncology and other targeted therapies – has redefined packaging operations. These compounds, often requiring occupational exposure limits in the low nanogram range, demand facilities

that combine containment precision with manufacturing and packaging efficiency.

Modern high-potent packaging suites exemplify this evolution. Built around stringent airflow management, segregated zones, and dedicated HVAC systems with up to 20 air changes per hour, they maintain negative-pressure environments that prevent cross-contamination. Many facilities now perform SMEPAC testing (using surrogate materials to model particulate behaviour) to validate containment performance before any commercial run.

Automated inspection systems play an equally vital role. High-potent blister and bottling lines integrate multiple verification layers – infrared and electromagnetic sensors for tablet counting, vision systems to confirm label accuracy, and in-line serialisation to comply with the EU Falsified Medicines Directive and U.S. DSCSA.

Even the materials used in such environments are specialised: low-roughness stainless-steel surfaces (Ra ≤ 0.8 µm) that resist product adhesion and enable manual or semi-automated cleaning; wall panels and flooring engineered for smooth, easy decontamination; and sealed dust extraction systems designed for micro-particulate capture.

The design philosophy is one of containment through flow: unidirectional personnel and material movement, airlocks separating primary and secondary packaging zones, and "de-boxing rooms" to remove cardboard before entry. These controls, once confined to manufacturing, now extend seamlessly into packaging.

The commercial driver is clear. The rise of small-batch, high-value therapies means packaging lines must handle frequent changeovers without compromising safety. Achieving that balance – throughput with containment – represents the cutting edge of modern pharmaceutical packaging engineering.

**Injectable and Drug-Device Combination Packaging**

If OSD packaging is evolving toward agility, injectable and drug-device combination products (DDCPs) embody complexity. The market for self-injection devices alone is expected to reach USD 97 billion by 2031 – driven by biologics, chronic disease management, and the shift toward home-based care.

Packaging for these products sits at the intersection of sterility assurance, mechanical precision, and patient usability. Components must protect sensitive formulations from oxygen, moisture, and light while integrating seamlessly with delivery devices such as prefilled syringes, autoinjectors, or on-body injectors.

Best-in-class CDMOs now offer end-to-end solutions encompassing:

- Device assembly and functional testing – ensuring correct alignment, torque, and activation forces.

- Labelling and serialisation – maintaining full traceability through global supply chains.
- Cold-chain management – with validated environments from 2 °C down to –196 °C for cell and gene therapies.
- Kitting and final packaging – combining multiple components (device, instructions, ancillaries) into a single, compliant unit.

Equally important is human factors engineering. Regulatory authorities increasingly expect usability studies to demonstrate that patients – including those with dexterity or vision impairments – can safely and effectively administer therapy. Packaging design therefore influences not only logistics and safety but also regulatory approval.

The manufacturing infrastructure supporting these capabilities is changing rapidly. Device assembly lines are now modular and scalable, running from small pilot operations (a few units per minute) to fully automated commercial systems (hundreds of units per minute). Serialisation and aggregation are integrated from the outset, allowing serialised data to flow through manufacturing execution systems and enterprise resource planning platforms.

These operational advances are transforming injectables packaging from a linear finishing step into a precision manufacturing discipline in its own right – one that unites engineering, patient experience, and data integrity.

**Balancing Sustainability with Safety and Performance**

Perhaps no challenge is more pressing – or more difficult – than embedding sustainability into pharmaceutical packaging. The market for sustainable pharma packaging is projected to grow from USD 99 billion in 2024 to nearly USD 377 billion by 2034, at a CAGR of over 14 %.

However, implementing environmentally responsible materials within a highly regulated, safety-critical industry is far from straightforward. For oral solid doses, transitioning to recyclable or bio-based films and cartons is feasible; for injection devices, it is considerably harder. Materials must maintain barrier properties, chemical compatibility, and sterility – without compromising device function or patient safety.

To address this, packaging engineers are turning to life-cycle assessment (LCA)


tools to quantify environmental impact and identify "hotspots" for improvement across materials, transport, and disposal. Even small interventions can deliver significant results: resizing or reconfiguring secondary packs can cut packaging volume by up to 30 %, reduce cold-chain footprint, and save hundreds of thousands of litres of water or fuel annually.

Paper-based or bio-derived alternatives, certified under ISCC+ mass-balance standards, are beginning to replace petroleum plastics in certain device trays and cartons. Hybrid approaches – for instance, downgauged thermoplastics reinforced with renewable fillers – maintain strength and barrier properties while lowering carbon impact.

But sustainability extends beyond materials. It encompasses process efficiency (shorter print runs, less overstock), logistics optimisation (regional packaging to reduce transport), and circular design (easier separation of recyclable components). In this respect, digital printing and late-stage customisation directly support environmental goals by reducing waste and obsolescence.

Ultimately, sustainable packaging is less about a single innovation than a systems approach – one that unites materials science, engineering, usability, and data to deliver measurable carbon and cost reductions without compromising quality.

**Integration and Lifecycle Thinking**

A defining trend across the industry is the integration of clinical and commercial packaging operations. Historically, clinical supply and commercial manufacturing existed in separate silos; today, the ability to scale seamlessly from early-phase studies to market launch is a critical differentiator.

Integrated CDMOs have begun designing packaging networks that can:

- Support both small-batch and large-scale production within the same validated framework.
- Transition from clinical randomisation and blinding to commercial serialisation without re-validation.
- Employ common packaging materials and components across phases to streamline qualification.
- Combine packaging data with manufacturing execution and ERP systems for full product traceability.

This "bench-to-shelf" philosophy improves not only efficiency but also quality governance. It minimises handovers, reduces transport risk for high-value or temperature-sensitive products, and enables rapid response to regulatory changes.

In practice, the integration of manufacturing, packaging, and distribution is reinforced by digitalisation. Real-time data capture, predictive maintenance, and AI-driven forecasting are reshaping how packaging lines are scheduled and optimised. The future lies in connected packaging ecosystems that unite material suppliers, manufacturers, and distributors through shared digital standards.

**Toward Packaging as a Strategic Discipline**

Across oral solids, injectables, and combination products, several principles now define best practice in pharmaceutical packaging:

1. Agility over scale-smaller, more flexible runs beat monolithic production in a fragmented global market.
2. Containment by design-high-potent

handling must extend seamlessly into packaging.

3. Integration across the lifecycle-clinical and commercial packaging should operate as a continuum.
4. Sustainability with accountability-measurable LCAs, recyclable materials, and process efficiency will become baseline expectations.
5. Patient-centric functionality-usability, labelling clarity, and device ergonomics must guide packaging decisions.
6. Digital traceability-serialisation and data integration are now central to compliance and supply-chain resilience.

Packaging, once a finishing step, is now a strategic enabler – shaping how effectively therapies reach patients, how sustainably they are produced, and how rapidly companies can adapt to change.

**Conclusion: The New Front Line of Therapeutic Delivery**

The coming decade will see pharmaceutical packaging evolve from logistics to leadership-becoming the interface where science, regulation, and sustainability converge. CDMOs and pharma manufacturers that treat packaging as an innovation platform rather than a constraint will gain decisive advantage.

Late-stage customisation is redefining responsiveness; high-potent containment sets new safety benchmarks; device and combination product packaging blends engineering with empathy; and sustainability reframes the industry's environmental footprint.

The most successful organisations will integrate these disciplines – not as isolated capabilities, but as elements of a holistic, digitally connected value chain from molecule to market. In that future, packaging is not the last step in drug delivery. It is the first signal that innovation has reached the patient – safely, efficiently, and responsibly.

**REFERENCES**


1. https://www.grandviewresearch.com/horizon/outlook/pharmaceutical-packaging-market-size/global
2. https://www.precedenceresearch.com/pharmaceutical-contract-packaging-market
3. https://www.precedenceresearch.com/sustainable-pharmaceutical-packaging-market



**Paul Smallman**

Paul Smallman is a senior technical leader at PCI Pharma Services, bringing over 30 years of expertise in pharmaceutical packaging and drug delivery systems. At PCI, Paul plays a key role in delivering innovative technical solutions across the entire drug product lifecycle – from stability studies and clinical trial supplies to full-scale commercial launch. He leads cross-functional technical teams to ensure the successful design, development, and implementation of packaging formats and processes that meet the unique needs of each client. Partnering with a wide range of small, mid-size, and large biopharmaceutical companies, Paul has a proven track record of directing complex projects from concept to commercialisation, helping to bring life-changing treatments to patients around the world.